Study of SR604 in healthy people and those with bleeding disorders
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new drug called SR604 to see if it is safe and how it works in the body. It is for healthy men and for people with hemophilia A, hemophilia B, or factor VII deficiency who have frequent bleeding or are on preventive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy male aged 18 to 55, or you have hemophilia A, hemophilia B, or factor VII deficiency and are between 18 and 60 years old.
- For the bleeding disorder part, you must have severe hemophilia A (<1% factor VIII), severe or moderately severe hemophilia B (≤2% factor IX), or severe factor VII deficiency (<10% activity).
- You must not have a history of blood clots, stroke, or a family history of clotting problems like factor V Leiden or protein C deficiency.
- You must be willing to stop your current bleeding treatment for a short time before and during the study (weaning period).
- You must have medical records of your bleeding episodes for at least 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
This trial is testing a new injection called SR604 in people with congenital factor VII deficiency, a rare bleeding disorder. The study will check if the drug is safe and effective at preventing or treating bleeding episodes.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.